

### AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1 – 21. (CANCELLED)

22. (NEW) An isolated nucleic acid encoding a polypeptide having at least 95% sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6); or

(f) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein said polypeptide is associated with the formation or growth of lung or colon tumor.

23. (NEW) The isolated nucleic acid of Claim 22, encoding a polypeptide having at least 96% sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

Appl. No. : Not Yet Assigned  
Filed : Herewith

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6); or

(f) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein said polypeptide is associated with the formation or growth of lung or colon tumor.

24. (NEW) The isolated nucleic acid of Claim 22, encoding a polypeptide having at least 97% sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6); or

(f) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein said polypeptide is associated with the formation or growth of lung or colon tumor.

25. (NEW) The isolated nucleic acid of Claim 22, encoding a polypeptide having at least 98% sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6); or

(f) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein said polypeptide is associated with the formation or growth of lung or colon tumor.

26. (NEW) The isolated nucleic acid of Claim 22, encoding a polypeptide having at least 99% sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) the amino acid sequence of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6); or

(f) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203661;

wherein said polypeptide is associated with the formation or growth of lung or colon tumor.